ReviewFrontiers in immunology2026
Clinical applications and challenges of CD40/CD40L signaling regulation in autoimmune diseases.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CD40-CD40L axis is a central costimulatory pathway that links innate and adaptive immunity and contributes to autoimmune inflammation. However, CD40 signaling does not operate in the same way across cell types, and these differences are relevant to both therapeutic efficacy and safety. In this review, we discuss the molecular features of CD40 and CD40L, the TRAF-dependent signaling pathways activated downstream of CD40, and the distinct cellular responses observed in B cells, dendritic cells, and macrophages. We also examine how dysregulated CD40/CD40L signaling contributes to key pathological features of Rheumatoid arthritis, Systemic lupus erythematosus, and Sjögren's syndrome, including ectopic germinal center reactions, pathogenic autoantibody production, and chronic tissue inflammation. Platelet-derived CD40L and CD40 expression on vascular cells may also help explain the thromboembolic complications observed with early CD40/CD40L-targeted biologics. Current evidence suggests that safer therapeutic targeting of this pathway will require greater selectivity, particularly with respect to cell-specific signaling and Fc-mediated adverse effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.